{
    "clinical_study": {
        "@rank": "154874", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/PCA added Standard Hormone Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Combination therapy with DCVAC/PCa added on to a Standard of Care Hormone Therapy"
            }, 
            {
                "arm_group_label": "Standard of Care Hormone Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/PCa  added onto hormone therapy can\n      improve PSA progression times for patients with Metastatic Prostate Cancer (PCa)."
        }, 
        "brief_title": "Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Use of vaccine to improve Prostate Specific Antigen (PSA) levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male 18 years and older\n\n          -  Histologically confirmed prostate adenocarcinoma\n\n          -  Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy)\n\n          -  Androgen deprivation therapy using Luteinizing-hormone-releasing hormone ( LHRH)\n             analogues commenced at least one month and at most three months prior randomization\n             or orchiectomy performed at least one month and at most three months prior\n             randomization\n\n          -  Serum testosterone level at screening  (\u2264 1.7 nmol/l, resp. \u2264 50 ng/dL)\n\n          -  Eastern Cooperative Oncology Group (ECOG)  0-2\n\n        Exclusion Criteria:\n\n          -  Confirmed brain and/or leptomeningeal metastases\n\n          -  Prior or ongoing chemotherapy for prostate cancer\n\n          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater\n\n          -  Other uncontrolled intercurrent illness\n\n          -  Treatment with immunotherapy against PCa\n\n          -  Clinically significant cardiovascular disease\n\n          -  Active autoimmune disease requiring treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107391", 
            "org_study_id": "SP002", 
            "secondary_id": "2011-004986-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCVAC/PCA added Standard Hormone Therapy", 
                "description": "Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy", 
                "intervention_name": "DCVAC/PCa", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard of Care Hormone Therapy", 
                "description": "Standard of Care Hormone Therapy as an Active Comparator", 
                "intervention_name": "Leuprolide acetate", 
                "intervention_type": "Drug", 
                "other_name": "Lupron"
            }, 
            {
                "arm_group_label": "Standard of Care Hormone Therapy", 
                "description": "Standard of Care Hormone Therapy as an Active Comparator", 
                "intervention_name": "Goserelin Acetate", 
                "intervention_type": "Drug", 
                "other_name": "Zoladex"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Leuprolide", 
                "Goserelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "Prostate Cancer", 
            "Biological", 
            "Vaccine", 
            "Androgen Deprivation Therapy"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jablonec nad Nisou", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jihlava", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kromeriz", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liberec", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mnisek pod Brdy", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pelhrimov", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plzen", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 10", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uherske Hradiste", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients with PSA Progression", 
            "safety_issue": "No", 
            "time_frame": "104 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with Progression of Disease", 
                "safety_issue": "No", 
                "time_frame": "0, 6, 16, 28, 40, 52, 65, 78, 91, 104 weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104  weeks"
            }, 
            {
                "measure": "Frequency of Skeletal Related Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104  weeks"
            }, 
            {
                "description": "European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30", 
                "measure": "Changes in Quality of Life (QOL) assessed by EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks"
            }, 
            {
                "description": "Pain Scale from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30", 
                "measure": "Changes in Pain assessed by EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}